DE69823501D1 - Verwendung von wolinella succinogenes asparaginase zur behandlung von asparagin-abhängiger krankheiten - Google Patents

Verwendung von wolinella succinogenes asparaginase zur behandlung von asparagin-abhängiger krankheiten

Info

Publication number
DE69823501D1
DE69823501D1 DE69823501T DE69823501T DE69823501D1 DE 69823501 D1 DE69823501 D1 DE 69823501D1 DE 69823501 T DE69823501 T DE 69823501T DE 69823501 T DE69823501 T DE 69823501T DE 69823501 D1 DE69823501 D1 DE 69823501D1
Authority
DE
Germany
Prior art keywords
asparaginase
succinogenes
asparagine
methods
succinogenes asparaginase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69823501T
Other languages
English (en)
Other versions
DE69823501T2 (de
Inventor
L Durden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital Los Angeles
Original Assignee
Childrens Hospital Los Angeles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Los Angeles filed Critical Childrens Hospital Los Angeles
Publication of DE69823501D1 publication Critical patent/DE69823501D1/de
Application granted granted Critical
Publication of DE69823501T2 publication Critical patent/DE69823501T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/82Asparaginase (3.5.1.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/50Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE69823501T 1997-06-09 1998-06-09 Verwendung von wolinella succinogenes asparaginase zur behandlung von asparagin-abhängiger krankheiten Expired - Lifetime DE69823501T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4908597P 1997-06-09 1997-06-09
US49085P 1997-06-09
PCT/US1998/011905 WO1998056410A1 (en) 1997-06-09 1998-06-09 Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence

Publications (2)

Publication Number Publication Date
DE69823501D1 true DE69823501D1 (de) 2004-06-03
DE69823501T2 DE69823501T2 (de) 2005-04-07

Family

ID=21957977

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69823501T Expired - Lifetime DE69823501T2 (de) 1997-06-09 1998-06-09 Verwendung von wolinella succinogenes asparaginase zur behandlung von asparagin-abhängiger krankheiten

Country Status (8)

Country Link
US (2) US6251388B1 (de)
EP (1) EP0988050B1 (de)
AT (1) ATE265226T1 (de)
AU (1) AU752370B2 (de)
CA (1) CA2295980A1 (de)
DE (1) DE69823501T2 (de)
ES (1) ES2217566T3 (de)
WO (1) WO1998056410A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6991788B1 (en) 1997-06-09 2006-01-31 Childrens Hospital Los Angeles Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence
WO1999039732A1 (en) * 1998-02-09 1999-08-12 Aventis Pharmaceuticals Products Inc. Pharmaceutical compositions comprising peg-asparaginase for the treatment of hiv infections
US6689762B1 (en) 1998-02-09 2004-02-10 Enzon Pharmaceuticals, Inc. Composition and methods for treatment of HIV infection
AU4030200A (en) * 1999-04-02 2000-10-23 Children's Hospital Of Los Angeles Use of asparaginase and glutaminase to treat autoimmune disease and graft versushost disease
JP2003506409A (ja) * 1999-08-06 2003-02-18 アヴェンティス ファーマシューティカルズ インコーポレイテッド Hiv感染の治療用組成物及び方法
AU2002332371A1 (en) * 2001-08-22 2003-03-10 Gosudarstvennoe Uchrezhdenie Nauchno-Issledovatelsky Institut Biomeditsinskoy Khimii Im. Orekhovicha Recombinant l-asparaginase less thanigreater thanerwinia caratovoraless than/igreater than
EP1896524A1 (de) * 2005-05-27 2008-03-12 Formerol Limited Handformbares material
NZ599631A (en) * 2006-01-30 2013-08-30 Univ Georgia State Res Found Induction and stabilization of enzymatic activity in microorganisms
US7943549B2 (en) 2007-04-02 2011-05-17 Georgia State University Research Foundation, Inc. Biological-based catalyst to delay plant development processes
FI20070455A0 (fi) * 2007-06-08 2007-06-08 Reagena Ltd Oy Menetelmä syöpäsairauksien tai tulehdussairauksien hoitoon
WO2010023195A2 (en) 2008-08-26 2010-03-04 Kyon Biotech Ag Compositions and methods for treating cancer
WO2013055699A1 (en) * 2011-10-10 2013-04-18 Children's Hospital Los Angeles Novel asparaginase and methods for treating diseases associated with asparagine dependence
US10004237B2 (en) 2013-03-14 2018-06-26 Georgia State University Research Foundation, Inc. Inhibiting or reducing fungal growth
US9993005B2 (en) 2013-03-14 2018-06-12 Georgia State University Research Foundation, Inc. Preventing or delaying chill injury response in plants
EP3036318A1 (de) * 2013-08-20 2016-06-29 Chr. Hansen A/S Verfahren zum wachstum von bakterienzellen
RU2562166C1 (ru) * 2014-10-09 2015-09-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика") ГИБРИДНЫЙ БЕЛОК НА ОСНОВЕ L-АСПАРАГИНАЗЫ Wolinella succinogenes, ШТАММ Escherichia coli - ПРОДУЦЕНТ ГИБРИДНОГО БЕЛКА (ВАРИАНТЫ) И СПОСОБ ПОЛУЧЕНИЯ ГИБРИДНОГО БЕЛКА, ОБЛАДАЮЩЕГО ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТЬЮ
WO2018085493A1 (en) * 2016-11-04 2018-05-11 Georgia State University Research Foundation, Inc. Endotoxin free asparaginase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1807303A1 (de) * 1968-11-06 1970-06-04 Bayer Ag Partiell acylierte L-Asparaginasen
DE2039061A1 (de) * 1970-08-06 1972-02-10 Bayer Ag Partiell amidierte L-Asparaginasen
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US5693516A (en) * 1995-11-27 1997-12-02 Novo Nordisk Biotech, Inc. Method for solubilizing proteins in organic solvents

Also Published As

Publication number Publication date
US6251388B1 (en) 2001-06-26
AU8254498A (en) 1998-12-30
US20020102251A1 (en) 2002-08-01
WO1998056410A9 (en) 1999-04-08
EP0988050B1 (de) 2004-04-28
AU752370B2 (en) 2002-09-19
DE69823501T2 (de) 2005-04-07
EP0988050A1 (de) 2000-03-29
ES2217566T3 (es) 2004-11-01
ATE265226T1 (de) 2004-05-15
WO1998056410A1 (en) 1998-12-17
CA2295980A1 (en) 1998-12-17

Similar Documents

Publication Publication Date Title
ATE265226T1 (de) Verwendung von wolinella succinogenes asparaginase zur behandlung von asparagin- abhängiger krankheiten
EA200400312A1 (ru) АНТАГОНИСТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ hTNFSF13b ЧЕЛОВЕКА
ATE437648T1 (de) Apolipoprotein a-i agonisten und deren verwendung zur behandlung dyslipidämischer erkrankungen
DE3750451T2 (de) Rekombinanter menschlicher endothelzellenwachstumsfaktor.
CY1111120T1 (el) Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση
ES8602121A1 (es) Procedimiento para producir un vehiculo de expresion para la formacion de uroquinasa humana
DE69730038D1 (de) Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
DE60331546D1 (de) Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung
ATE320488T1 (de) Mutanten des lag-3 proteins, ihre expression und verwendung
NZ515678A (en) Human GIL-19/AE289 proteins and polynucleotides encoding same
HUP0500637A2 (hu) Neublasztin polimer konjugátumai és alkalmazási eljárásai
ATE153069T1 (de) Vektoren und zusammensetzungen zur expression von glykosilationsmutanten des menschlichen proteins- c
DE69331813T4 (de) Verfahren zur Detektion und Behandlung von Individuen mit abnormal hla-a2/tyrosinase-peptidantigenen exprimierenden Zellen
WO2001088085A3 (en) Novel bee venom polypeptides and methods of use thereof
ATE112317T1 (de) Bcrf1-proteine als inhibitoren von interferon- g(g).
DE60036555D1 (de) Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter
WO2000063415A8 (en) Dna encoding the human vanilloid receptor vr1
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
ATE384739T1 (de) Für den menschlichen vanilloid-rezeptor vr3 kodierende dns
EA200401390A1 (ru) N-ацетилглюкозамин-6-фосфатдеацетилаза человека, взаимодействующая с каспазой-8, и способы ее применения
ES8802441A1 (es) Procedimiento para preparar laminina humana
HUP9900789A2 (hu) Lefelé irányuló szabályozásra rezisztens C3 konvertáz
DE59410423D1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
DE69829995D1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
DE60229924D1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition